The neonatal Fc receptor (FcRn): From Biology to Therapy

  • 82k

    Total downloads

  • 401k

    Total views and downloads

About this Research Topic

Submission closed

Background

Antibodies are the adapter molecules that link recognition of foreign antigens or pathogens to effector mechanisms of the immune system. Of the five antibody classes, IgG is the most prevalent in blood where it protects against intruders and toxins. Importantly, IgG is transported from mother to fetus or newborn, and furthermore, has an unusual long half-life of three weeks in humans. Both features are solely due to its interaction with a cellular receptor named the neonatal Fc receptor (FcRn), also known as the Brambell receptor. FcRn resides within endosomal compartments. It directs IgG taken up by pinocytosis back out of cells to the circulation, and thereby rescues IgG from lysosomal degradation. Thus, FcRn serves as a homeostatic regulator of IgG catabolism and directs the biodistribution of IgG.

Recent years have also witnessed an enormous increase in our knowledge of FcRn functions beyond its well-characterized role in half-life regulation, as it transports IgG within and across many different cell types in the body, such as endothelial cells, cells of the placenta, mucosal epithelial cells, kidney cells, liver cells and dendritic cells. In dendritic cells, FcRn is engaged in orchestration and delivery of IgG bound antigens to processing pathways that promote presentation on MHC class II molecules and cross-presentation on MHC class I molecules, while unbound IgG is recycled and rescued, like in endothelial cells lining the blood vessels. Moreover, expression of FcRn has been identified in many other tissues, including the blood-brain barrier, the glomerular filters of the kidneys and the liver. These findings merit further studies on the diverse roles of FcRn at these body sites.

Beside IgG, FcRn binds albumin, which is also protected from intracellular degradation. While IgG combats infections, and is produced by plasma cells, albumin is exclusively produced by hepatocytes and serves as a multi-transporter that fulfils essential roles as a carrier of an array of nutrients,
hormones, drugs and toxins throughout the body. Albumin is the most abundant protein in blood due to the rate of synthesis and its interaction with FcRn.

Importantly, since IgG and albumin are extensively explored as therapeutics or carrier of drugs, there is an intense interest in engineering of novel variants with modulated FcRn binding kinetics tailored for improved pharmacokinetics and therapeutic efficacy. FcRn is a major histocompatibility complex (MHC) class I-related receptor, and knowledge of how FcRn binds both its ligands and ligand variants is of great importance.

In this research topic, we aim to provide a comprehensive state-of the art overview of current research on the versatile functions of FcRn, and encourage submission of research articles, reviews and perspectives. Considering the clinical significance of FcRn, we also aim to provide a range of articles summarizing the current knowledge on how our understanding of FcRn functions that can be translated into development of new therapeutics.

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Frequently asked questions

  • Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

    Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

  • The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

    Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

  • As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

    A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

  • Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

    In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

  • Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

    As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

    Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

  • Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

    Check available article types here 

  • Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

    Suggest your topic here 

  • A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

    The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

  • As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

    You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

  • As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

  • If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

  • Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

  • Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

  • As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

    Find out more about our Research Topics

  • Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

    Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

  • In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.